Tags: Drug.
Liraglutide (NN2211) marketed under the brand name Victoza is a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) developed by Novo Nordisk for the treatment of type 2 diabetes. The product was approved by the European Medicines Agency (EMA) on July 3 2009 and by the U.S. Food and Drug Administration (FDA) on January 25 2010.Liraglutide is marketed under the brandname Victoza in the U.S. India Canada Europe and Japan.
